Nirmatrelvir + ritonavir - Pfizer
Alternative Names: nirmatrelvir [PF-07321332] tablets and ritonavir tablets; Nirmatrelvir plus ritonavir - Pfizer; Nirmatrelvir+ritonavir - Pfizer; nirmatrelvir/ritonavir; PAXLOVID; PF 07321332 plus ritonavir - Pfizer; PF 07321332+ritonavir - Pfizer; PF-07321332/ritonavirLatest Information Update: 22 Jun 2024
At a glance
- Originator Pfizer
- Class Amides; Amines; Antivirals; Aza compounds; Carbamates; Fluorinated hydrocarbons; Heterocyclic bicyclo compounds; Nitriles; Pyrrolidinones; Small molecules; Thiazoles
- Mechanism of Action Coronavirus-3C-like-proteinase inhibitors; HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 04 Jun 2024 Pfizer re-initiates the phase II/III EPIC-PEDS trial in COVID-2019 infections (In children, In adolescents, In infants, In neonates) in USA, Bulgaria, Hungary, Mexico, South Africa, United Kingdom (PO, Tablets) (NCT05261139) (EudraCT2022-000075-39)
- 02 May 2024 Pfizer plans a phase I trial for COVID-19 infections (In Volunteers) in 2025 (PO,Tablet) (NCT06397144)
- 24 Apr 2024 Pfizer reinitiates enrolment in a phase I trial for COVID-2019 infections (In adults) in USA (PO) (NCT05386472)